Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

Abstract

The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein cholesterol level in agreement with National Cholesterol Education Program Adult Treatment Panel guidelines. The initial treatment should be lifestyle therapy; a combination of diet modification and drug therapy may also be considered. In patients with severe or very severe hypertriglyceridemia, a fibrate should be used as a first-line agent.

Beating the urine drug test – a case report on niacin toxicity

“…It is available by prescription either as an immediate-release, sustained-release or extended-release formulation (Table 3). However, there are many over-the-counter (OTC) formulations of immediate-release and sustained-release niacin [2]. …”

An Interesting Case of Hypertriglyceridaemic Pancreatitis

“…in up to 47% of the cases [1]. To consider hypertriglyceridaemia as the cause of acute pancreatitis, the serum level should be more than 1000mg/dl [2,5]. Our patient had hypertriglyceridaemia of more than 1000mg/dl.…”

Klinikinis Atvejis: Hiperlipideminis Pankreatitas

“…Todėl monoterapija heparinu nerekomenduojama ir įtraukti jį į gydymo schemą reiktų kartu su insulinu, kuris. aktyvindamas lipoproteinlipazę, tikėtina apsaugo ją nuo metabolizmo [14,32]. Literatūros duomenimis, nėra atlikta tyrimų, kuriais remiantis būtų galima rinktis heparino skyrimo būdą.…”